Evaluating behavioral disorders in rat after treatment with candesartan in ischemic stroke
Elmira Pasban 1, 2  
More details
Hide details
Department of Biology, Fars Science and Research Branch, Islamic Azad University, Fars, Iran
Department of Biology, Shiraz Branch, Islamic Azad University, Shiraz, Iran
Online publish date: 2018-04-20
Publish date: 2018-04-20
Electron J Gen Med 2018;15(4):em52
Stroke is the third cause of death and disability in many human societies. Millions of people suffer from the disease each year. Ischemic stroke accounts for 83% of all cases of stroke. This type of stroke is caused by permanent or temporary stoppage of the bloodstream of a part of the brain. Due to the complexity of the pathophysiologic factors contributing to the ischemic injury of the brain, there is still no effective treatment for it. In the present study, the effects of concomitant treatment of candesartan as an antagonist of type I angiotensin II receptor antagonist in rat localized ischemic assay are presented. In this study, 81 male Sprague-Dawley rats were studied in three groups (n = 27), control, ischemic control and candesartan treatment. Local brain ischemia was developed for 90 minutes using an intermediate artery occlusion technique and continued with 24-hour reperfusion. Each main group was randomly divided into three subgroups. Neurological disorders were evaluated using a special test. Occurrence of ischemia in animals: The ischemic control group caused severe motor and sensory impairment with significant lesion in the left hemisphere. Administration of candesartan significantly improves sensory and motor impairment compared with the ischemic control group. Was able to protect against the onset of ischemic stroke in a local rat brain ischemia test. Candesartan therapy improves sensory and motor impairment due to ischemic stroke.
1. Panahpour H, Dehghan G. Effects of Renin-Angiotensin System Inhibition on Ischemic Brain Edema Formation and Blood-Brain Barrier Disruption Following Focal Cerebral Ischemia in Rat. Journal of Ardabil University of Medical Sciences. 2011;11(1):14-23.
2. Liu R, Liu Q, He S, Simpkins JW, Yang S-H. Combination therapy of 17β-estradiol and recombinant tissue plasminogen activator for experimental ischemic stroke. Journal of Pharmacology and Experimental Therapeutics. 2010;332(3):1006-1012. https://doi.org/10.1124/jpet.1... PMid:19952306 PMCid:PMC2835431.
3. Ross R. Atherosclerosis—an inflammatory disease. New England journal of medicine. 1999;340(2):115-126. https://doi.org/10.1056/NEJM19... PMid:9887164.
4. Faure S, Oudart N, Javellaud J, Fournier A, Warnock DG, Achard J-M. Synergistic protective effects of erythropoietin and olmesartan on ischemic stroke survival and post-stroke memory dysfunctions in the gerbil. Journal of hypertension. 2006;24(11):2255-2261. https://doi.org/10.1097/01.hjh... PMid:17053548.
5. Panahpour H. Induction of Focal Cerebral Ischemia by Continuous Recording of Cerebral Blood Flow Using Laser Doppler Flowmeter in Rat. Journal of Ardabil University of Medical Sciences. 2011;11(4):316-328.
6. Tarnacka B, Gromadzka G, Członkowska A. Increased circulating immune complexes in acute stroke. Stroke. 2002;33(4):936-940. https://doi.org/10.1161/01.STR... PMid:11935040.
7. Van Exel E, Gussekloo J, De Craen AJM, Bootsma-Van Der Wiel A, Frölich M, Westendorp RGJ. Inflammation and stroke. Stroke. 2002;33(4):1135-1138. https://doi.org/10.1161/01.STR... PMid:11935072.
8. Panahpour H, Nekooeian AA, Dehghani GA. Candesartan attenuates ischemic brain edema and protects the blood-brain barrier integrity from ischemia/reperfusion injury in rats. Iran Biomed J. 2014;18(4):232-238. PMid:25326022 PMCid:PMC4225063.
9. Panahpour H, Nouri M. Post-Ischemic Treatment with candesartan protect from cerebral ischemic/reperfusioninjury in normotensive rats. Int J Pharm Pharm Sci. 2012;4(4): 286-289.
10. Atif F, et al. Combination treatment with progesterone and vitamin D hormone is more effectivr than monotherapyis ischemic stroke: the tole of BDNF/TrkB/Erk1/2 signaling in neuroprotection. Neuropharmacology. 2013;67:78-87. https://doi.org/10.1016/j.neur... PMid:23154302 PMCid:PMC3568940.
11. Gunn A, Bobeck EN, Weber C, Morgan MM. The influence of non-nociceptive factors on hot-plate latency in rats. J Pain. 2011;12(2):222-227. https://doi.org/10.1016/j.jpai... PMid:20797920 PMCid:PMC3312470.
12. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20(1):84-91. https://doi.org/10.1161/01.STR... PMid:2643202.
13. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends in neurosciences. 1999;22(9):391-397. https://doi.org/10.1016/S0166-....
14. Warr O, Takahashi M, Attwell D. Modulation of extracellular glutamate concentration in rat brain slices by cystine‐glutamate exchange. The Journal of physiology. 1999;514(3):783-793. https://doi.org/10.1111/j.1469... PMid:9882750 PMCid:PMC2269108.
15. Zivin JA, Grotta JC. Animal stroke models. They are relevant to human disease. Stroke. 1990;21(7):981-983. https://doi.org/10.1161/01.STR....
16. Pandian JD. Re-canalization in acute ischemic stroke: the strategies. Neurology India. 2009;57(1):20. https://doi.org/10.4103/0028-3... PMid:19305071.
17. Awad AS. Effect of combined treatment with curcumin and candesartan on ischemic brain damage in mice. Journal of Stroke and Cerebrovascular Diseases. 2011;20(6):541-548. https://doi.org/10.1016/j.jstr... PMid:20719539.